Outlook Therapeutics (OTLK) Accumulated Expenses (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Accumulated Expenses data on file, last reported at $718606.0 in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $718606.0, up 26.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $718606.0 (up 26.98% YoY), and the FY2025 annual result was $1.6 million, up 57.05% from the prior year.
• Accumulated Expenses slipped to $718606.0 in Q1 2026 per OTLK's latest filing, from $1.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $8.3 million in Q2 2023 and troughed at $565909.0 in Q1 2025.
• A 5-year average of $2.2 million and a median of $1.6 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 1231173.54% in 2022, then slumped 89.19% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $2.7 million in 2022, then slumped by 59.48% to $1.1 million in 2023, then tumbled by 38.56% to $683479.0 in 2024, then jumped by 127.44% to $1.6 million in 2025, then slumped by 53.77% to $718606.0 in 2026.
• Business Quant data shows OTLK's Accumulated Expenses at $718606.0 in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.